Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 192

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 192
---
 the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase such number of Ordinary
Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest
price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public
offering. On March 31, 2025, we and the lenders entered into an amendment to the 2024 Loan Agreement to extend the maturity date until
the earlier of August 31, 2025, or the consummation of an IPO. On July 1, 2025, we entered into an amendment to the 2024 Loan Agreements
such that the 2024 Loan Agreement lenders shall be granted warrants to purchase up to 61,539 Ordinary Shares following the consummation
of this offering. During September 2025, the 2024 Loan Agreements have been extended until November 30, 2025.

<div align='center'>116</div>

On December 1, 2024,
we entered into a loan agreement with our Chief Executive Officer, or the December 2024 Loan Agreement, according to which accrued
payroll salary owed to him in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at
an 8% annual rate, and is due upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity,
the Company will pay to our Chief Executive Officer an aggregate risk premium equal to 30% of the loan amount (or approximately
$35,100 plus VAT). If a registration statement for an initial public offering is made effective no later than March 31, 2025, then
the maturity date will be extended to June 30, 2025. In addition, pursuant to the December 2024 Loan Agreement, upon the
consummation of this offering the Company will issue warrants, or the CEO Loan Warrants, exercisable for a period of three years
from the date of the issuance, to purchase such number of Ordinary Shares equal to two times the respective loan amount divided by
75% of the lowest price per Ordinary Share during the first five trading days following the consummation of this offering, at an
exercise price equal to 75% of the lowest price per Ordinary Share during the